Jiang Zaixin, Liu Haiwei, Qiu Miaohan, Li Jing, Zhao Wei, Zhang Donghong, Liu Daoshen, Na Kun, Li Yi, Han Yaling
State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, 83 Wenhua Road, Shenyang, 110016, China.
BMC Med. 2025 Feb 24;23(1):112. doi: 10.1186/s12916-025-03933-2.
Acute coronary syndrome (ACS) patients without standard modifiable cardiovascular risk factors (SMuRFs) have a higher risk of early mortality. However, little is known about their long-term outcomes, especially for patients undergoing percutaneous coronary intervention (PCI). This study aims to explore the long-term outcomes and identify independent factors associated with adverse clinical outcomes in patients with ACS undergoing PCI without SMuRFs.
This study used data from Optimal antiPlatelet Therapy for Chinese patients with Coronary Artery Disease (OPT-CAD) registry study. Clinical characteristics and outcomes of patients with and without SMuRFs were examined. The primary outcomes were major adverse cardia-cerebrovascular events (MACCE). The long-term (5 years) outcomes were compared between the without and with SMuRFs group in such cohort. An exploratory Cox proportional hazards regression was performed to identify the independent demographic and clinical predictors of the adverse clinical outcomes in the SMuRFs-absent cohort.
Among 5688 patients with ACS undergoing PCI, 392 (6.9%) were in the absence of SMuRFs and 5296 (93.1%) were in the presence of SMuRFs. There were no significant differences in MACCE rates between the two cohorts (9.44% vs. 9.76%, log-rank P = 0.90). Cox proportional hazards regression indicated that age (HR, 1.06; 95% CI, 1.03-1.10; P = 0.001) and thrombus lesions (HR, 2.58; 95% CI, 1.24-5.40; P = 0.011) were independently associated with MACCE in the SMuRFs-absent cohort.
Among patients with ACS undergoing PCI, SMuRFs-absent patients had similar MACCE rates when compared with those with one or more SMuRFs at 5 years. This suggests that effective intervention strategies and updated risk assessment models are urgently needed in the SMuRFs-absent cohort.
无标准可改变心血管危险因素(SMuRFs)的急性冠状动脉综合征(ACS)患者早期死亡风险较高。然而,对于他们的长期预后知之甚少,尤其是接受经皮冠状动脉介入治疗(PCI)的患者。本研究旨在探讨无SMuRFs的接受PCI的ACS患者的长期预后,并确定与不良临床结局相关的独立因素。
本研究使用了中国冠状动脉疾病患者优化抗血小板治疗(OPT-CAD)注册研究的数据。检查了有无SMuRFs患者的临床特征和结局。主要结局为主要不良心脑血管事件(MACCE)。比较了该队列中无SMuRFs组和有SMuRFs组的长期(5年)结局。进行探索性Cox比例风险回归以确定无SMuRFs队列中不良临床结局的独立人口统计学和临床预测因素。
在5688例接受PCI的ACS患者中,392例(6.9%)无SMuRFs,5296例(93.1%)有SMuRFs存在。两组队列的MACCE发生率无显著差异(9.44%对9.76%,对数秩检验P = 0.90)。Cox比例风险回归表明,年龄(HR,1.06;95%CI,1.03 - 1.10;P = 0.001)和血栓病变(HR,2.58;95%CI,1.24 - 5.40;P = 0.011)在无SMuRFs队列中与MACCE独立相关。
在接受PCI的ACS患者中,无SMuRFs的患者在5年时与有一个或多个SMuRFs的患者相比,MACCE发生率相似。这表明在无SMuRFs队列中迫切需要有效的干预策略和更新的风险评估模型。